5e5 of anti-GPC3 CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human Glypican 3, His Tag (Cat. No.GP3-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
2e5 of anti-Mucin-1 CAR-293 were stained with 100 μL of 0.1 μg/mL of Human Mucin-1, His Tag (Cat. No.MU1-H52H5) and negative control protein respectively, washed and then followed by PE anti-His Tag antibody and analyzed with FACS (Routinely tested).
参考文献Llovet, J.M., Kelley, R.K., Villanueva, A. et al. Hepatocellular carcinoma. NatRev Dis Primers 7, 6 (2021).https://doi.org/10.1038/s41572-020-00240-3Bruix, Jordi et al. Systemic treatment of hepatocellular carcinoma: An EASLposition paper. Journal of hepatology vol. 75,4 (2021): 960-974.doi:10.1016/j.jhep.2021.07.004Zhang, Renyu et al. Adoptive cell transfer therapy for hepatocellularcarcinoma. Frontiers of medicine vol. 13,1 (2019): 3-11. doi:10.1007/s11684-019-0684-xTseng, H, Xiong, W, Badeti, S. et al. Efficacy of anti-CD147 chimeric antigenreceptors targeting hepatocellular carcinoma. Nature Communications (2020)